EGFR and neuroendocrine carcinoma: For molecular alterations assessed by whole exome sequencing, the frequency of mutations in TP53, RB1, and EGFR in NEC and non-NEC components was 81.0/81.0%, 28.6/28.6%, and 42.9/42.9%, respectively.